“this time next year, hopefully, you know, in a pivotal study on APOL one, a couple other programs advancing through mid stage development”
→ Read the source episode
Maize announces initiation of a pivotal (Phase 3) trial for APOL1 kidney disease and reports advancement of at least two other programs into mid-stage clinical development (Phase 2).
Maize Therapeutics will determine within the next year whether its APOL1 and SLC6A19 programs pass phase two clinical trial scrutiny.
Heather Turner predicts LB Pharma will be on the cusp of schizophrenia approval, have successful bipolar depression phase three data, and positive phase two adjunctive MDD data by 2029.
Avalon will initiate Phase 3 trials for APL1 and APO2 following Phase 2 data readouts in 2027
Heather Turner predicts LB102 will demonstrate efficacy across multiple serious neuropsychiatric indications beyond schizophrenia.
Avalon will have Phase 2b data readout for APL1 (inhaled pirfenidone) in the second half of 2027
Avalon will have Phase 2 data readout for APO2 (inhaled nintedanib) in late 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.